Latest MedImmune Stories

GAITHERSBURG, Md., June 2 /PRNewswire/ -- MedImmune today announced that the U.S. Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants. The committee's recommendation will be considered by FDA reviewers in their evaluation of the Biologics License Application (BLA) for motavizumab. "We...

WILMINGTON, Del., June 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today it has received the 2010 EcoLeadership Award by the Alliance for Workplace Excellence (AWE) for the second consecutive year. The EcoLeadership Award recognizes companies that demonstrate their commitment to environmental sustainability practices such as energy efficiency, waste minimization and water conservation. (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) "AstraZeneca is...

BETHESDA, Md., May 27 /PRNewswire/ -- A new public-private partnership between AstraZeneca and NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will focus on supporting the work of the Drug-Induced Liver Injury Network (DILIN). DILIN is a group working to bring together essential scientific and financial resources to better understand drug-induce liver injury as well as effective screening, diagnostic and treatment options. Drug-induced liver injury, whether...

WILMINGTON, Del., May 25 /PRNewswire-FirstCall/ -- The Opportunity Center, Inc. (OCI) and AstraZeneca (NYSE: AZN) are partnering on an innovative program that gives Wilmington area school students with disabilities the opportunity to learn valuable job skills in a corporate setting. The program, called Path to Employment, is designed to increase career awareness and help students learn work requirements through modeling and examples. (Logo:...

Clearance will allow continued use of Simplexa Influenza A H1N1 (2009) test SILVER SPRING, Md., May 24 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced it has cleared the Simplexa Influenza A H1N1 (2009), a test for the 2009 H1N1 Influenza Virus in patients with signs and symptoms of respiratory infection. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Until this clearance, tests for 2009 H1N1 Influenza were only available through an Emergency...

Rogier van Doorn, Maciej Boni and colleagues analyze the initial H1N1 influenza outbreak in Ho Chi Minh City, Vietnam, including attempts at containment, and establishment of community transmission. To reconstruct the initial outbreak the researchers used reports from the Ministry of Health and clinical and laboratory data for people who were infected with 2009 H1N1 and isolated in hospital. Between April 27 and July 24, three-quarters of a million passengers arriving in the city on...

PRINCETON, N.J., May 17 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010. Soligenix's revenues for the first quarter of 2010 were approximately $336,000 as compared to $530,000 for the first quarter of 2009. The decreased revenues were primarily a result of decreases in National Institutes of Health (NIH) grant revenues as the Company...

BEIJING, May 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010. First Quarter 2010 Financial Highlights (comparisons to First Quarter 2009) -- Sales for the first quarter decreased 32% to $4.4 million -- Operating loss for the first quarter was $865,000, compared to operating income of $646,000 -- Net loss...

ROCKVILLE, Md., May 10 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced financial results for the first quarter ended March 31, 2010. Novavax reported a net loss of $11.4 million, or $0.11 per share, for the first quarter of 2010 compared to a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009. The primary reason for the increased loss for the first quarter of 2010 as compared to the same period in 2009 was due to higher research and...

HOBART, Australia, May 4 /PRNewswire/ -- In a breakthrough that offers new hope for the containment of influenza outbreaks, an Australian biotechnology company has isolated a natural extract from seaweed which has been shown to inhibit the H1N1 virus. The extract - known as Maritech® 926 - is a fucoidan compound derived from the Undaria pinnatifida species of seaweed. In vitro tests performed under contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the...